ArticleBlood advances2025
KDIGO-defined kidney dysfunction predicts long-term outcomes in a multicenter cohort of adults with sickle cell disease.
Article in Blood advances, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 5 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
5 citing papers in PubMed.
- Renin-angiotensin-aldosterone system inhibition exacerbates anemia in sickle cell disease.Blood · 2026Article
- Estimated glomerular filtration rate discordance and cardiopulmonary morbidity in sickle cell disease.Blood advances · 2026Article
- Natural History of Chronic Kidney Disease in Sickle Cell Disease.American journal of hematology · 2026Review
- Clinical evaluation of a novel urinary protein competitive immunoassay in the detection of proteinuria in adults with sickle cell disease.Frontiers in medicine · 2026Article
- Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
9 authors.
Funding
Abstract
abstractApproximately 15% of deaths in adults with sickle cell disease (SCD) are attributed to kidney failure. Although urine albumin-to-creatinine ratio (UACR) is recommended to screen for kidney damage, its utility in predicting long-term complications in SCD remains unclear. We investigated whether "Kidney Disease: Improving Global Outcomes (KDIGO)" algorithms used to assess kidney disease in the general population predicted chronic kidney disease (CKD) progression and mortality in a longitudinal cohort of 379 adults with SCD from 2 academic institutions. KDIGO criteria include UACR detected in 2 consecutive measurements ≥3 months apart and a heat map integrating UACR with estimated glomerular filtration rate. KDIGO-defined CKD was present in 39.8% of individuals in our SCD cohort. Over a median follow-up of 3.3 years, incremental KDIGO-defined UACR category independently predicted a twofold greater risk of CKD progression and 1.8-fold greater risk of mortality (P ≤ .05). KDIGO-defined CKD heat map strengthened the ability to predict CKD progression and mortality risk (P ≤ .0087). Our data provide clinical support for the screening utility of UACR based on repeated abnormal values ≥3 months apart. The KDIGO heat map further refines the risk of long-term outcomes among adults with SCD and should be applied to guide future studies for monitoring and intervention strategies.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.